Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Moleculin Biotech stock

Learn how to easily invest in Moleculin Biotech stock.

Moleculin Biotech is a biotechnology business based in the US. Moleculin Biotech shares (MBRX) are listed on the NASDAQ and all prices are listed in US Dollars. Moleculin Biotech employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Moleculin Biotech stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – MBRX. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Moleculin Biotech stock price (NASDAQ: MBRX)

Use our graph to track the performance of MBRX stocks over time.

Moleculin Biotech shares at a glance

Information last updated 2023-01-25.
Latest market close$1.26
52-week range$0.82 - $2.05
50-day moving average $1.23
200-day moving average $1.38
Wall St. target price$8.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.64

Buy Moleculin Biotech stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Moleculin Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Moleculin Biotech price performance over time

Historical closes compared with the close of $1.26 from 2023-01-25

1 week (2023-01-20) -1.56%
1 month (2022-12-27) 13.51%
3 months (2022-10-27) 35.15%
6 months (2022-07-27) -25.44%
1 year (2022-01-23) N/A
2 years (2021-01-27) 29.19%
3 years (2020-01-27) 39.66%
5 years (2018-01-26) 1.97

Moleculin Biotech financials

Gross profit TTM $0
Return on assets TTM -23.36%
Return on equity TTM -35.91%
Profit margin 0%
Book value $2.04
Market capitalisation $36.9 million

TTM: trailing 12 months

Moleculin Biotech share dividends

We're not expecting Moleculin Biotech to pay a dividend over the next 12 months.

Have Moleculin Biotech's shares ever split?

Moleculin Biotech's shares were split on a 1:6 basis on 31 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Moleculin Biotech shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Moleculin Biotech shares which in turn could have impacted Moleculin Biotech's share price.

Moleculin Biotech share price volatility

Over the last 12 months, Moleculin Biotech's shares have ranged in value from as little as $0.817 up to $2.05. A popular way to gauge a stock's volatility is its "beta".

MBRX.US volatility(beta: 1.96)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moleculin Biotech's is 1.9627. This would suggest that Moleculin Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Moleculin Biotech overview

Moleculin Biotech, Inc. , a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z. o.

Frequently asked questions

What percentage of Moleculin Biotech is owned by insiders or institutions?
Currently 2.944% of Moleculin Biotech shares are held by insiders and 10.464% by institutions.
How many people work for Moleculin Biotech?
Latest data suggests 13 work at Moleculin Biotech.
When does the fiscal year end for Moleculin Biotech?
Moleculin Biotech's fiscal year ends in December.
Where is Moleculin Biotech based?
Moleculin Biotech's address is: 5300 Memorial Drive, Houston, TX, United States, 77007
What is Moleculin Biotech's ISIN number?
Moleculin Biotech's international securities identification number is: US60855D2009
What is Moleculin Biotech's CUSIP number?
Moleculin Biotech's Committee on Uniform Securities Identification Procedures number is: 60855D101

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site